Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $64 |
| Gross Profit | $0 | $0 | $0 | -$64 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,431 | $8,505 | $7,423 | $14,630 |
| G&A Expenses | $2,570 | $1,664 | $3,004 | $0 |
| SG&A Expenses | $2,570 | $1,664 | $3,004 | $1,883 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,001 | $10,169 | $10,427 | $16,513 |
| Operating Income | -$8,001 | -$10,169 | -$10,427 | -$16,578 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $313 | $401 | $498 | $769 |
| Pre-Tax Income | -$7,688 | -$9,767 | -$9,930 | -$15,809 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,688 | -$9,767 | -$9,930 | -$15,809 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.16 | -0.17 | -0.27 |
| % Growth | 18.8% | 5.9% | 37% | – |
| EPS Diluted | -0.13 | -0.16 | -0.17 | -0.27 |
| Weighted Avg Shares Out | 60,127 | 60,046 | 59,887 | 59,485 |
| Weighted Avg Shares Out Dil | 60,127 | 60,046 | 59,887 | 59,485 |
| Supplemental Information | – | – | – | – |
| Interest Income | $789 | $872 | $981 | $1,240 |
| Interest Expense | $476 | $471 | $484 | $471 |
| Depreciation & Amortization | $64 | $62 | $61 | $64 |
| EBITDA | -$7,149 | -$9,234 | -$9,385 | -$15,274 |
| % Margin | – | – | – | – |